Difference between revisions of "Prostate-specific antigen"
Jump to navigation
Jump to search
Line 21: | Line 21: | ||
Where: | Where: | ||
:<math>volume = \frac{\pi}{6} H \times W \times L</math>.<ref>{{Cite journal | last1 = Eri | first1 = LM. | last2 = Thomassen | first2 = H. | last3 = Brennhovd | first3 = B. | last4 = Håheim | first4 = LL. | title = Accuracy and repeatability of prostate volume measurements by transrectal ultrasound. | journal = Prostate Cancer Prostatic Dis | volume = 5 | issue = 4 | pages = 273-8 | month = | year = 2002 | doi = 10.1038/sj.pcan.4500568 | PMID = 12627211 }} | |||
</ref> | |||
:H, W, L are the height, width and length. | |||
An alternate estimation of the volume is: | |||
:<math>volume = \frac{1}{2} D1 \times D2 \times D3</math>. | :<math>volume = \frac{1}{2} D1 \times D2 \times D3</math>. | ||
:D1, D2, D3 are the major axes. | :D1, D2, D3 are the major axes. |
Revision as of 18:53, 18 August 2014
Prostate specific antigen, abbreviated PSA, is marker that is quite specific for the prostate.
General
- Quantity in the serum used to screen for prostate cancer.
- PSA immunostain useful for classifying a carcinoma as prostate carcinoma.
Serum PSA
- Normal - typically < 4.0 ng/mL.
- Increases with age.[1]
Prostate specific antigen density
- Abbreviated PSAD.
Better predictor than (unadjusted) serum PSA for:
- Gleason score upgrading on prostatectomy.[2]
- Benign prostate gland versus prostate cancer.[3][4]
A forumla for PSAD
Benson et al.:[3]
Where:
- .[5]
- H, W, L are the height, width and length.
An alternate estimation of the volume is:
- .
- D1, D2, D3 are the major axes.
Note:
- The volume of an ellipsoid is:
- .
See also
References
- ↑ Ku JH, Ahn JO, Lee CH, et al. (September 2002). "Distribution of serum prostate-specific antigen in healthy Korean men: influence of ethnicity". Urology 60 (3): 475–9. PMID 12350489.
- ↑ Sfoungaristos S, Katafigiotis I, Perimenis P (2013). "The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era". Can Urol Assoc J 7 (11-12): E722–7. doi:10.5489/cuaj.374. PMC 3840515. PMID 24282465. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840515/.
- ↑ 3.0 3.1 Benson MC, Whang IS, Pantuck A, et al. (March 1992). "Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer". J. Urol. 147 (3 Pt 2): 815–6. PMID 1371554.
- ↑ Verma A, St Onge J, Dhillon K, Chorneyko A (June 2014). "PSA density improves prediction of prostate cancer". Can J Urol 21 (3): 7312–21. PMID 24978363.
- ↑ Eri, LM.; Thomassen, H.; Brennhovd, B.; Håheim, LL. (2002). "Accuracy and repeatability of prostate volume measurements by transrectal ultrasound.". Prostate Cancer Prostatic Dis 5 (4): 273-8. doi:10.1038/sj.pcan.4500568. PMID 12627211.